Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant cancer predisposition syndrome. HLRCC is characterized by the development of cutaneous leiomyomas, early-onset uterine leiomyomas, and HLRCC-associated renal cell cancer (RCC) and caused by germline fumarate hydratase (FH) deficiency. We investigated the genotypic and phenotypic characteristics of Korean patients with HLRCC. Methods: We performed direct sequencing analysis of FH in 13 patients with suspected HLRCC and their family members. A chromosomal microarray test was performed in female patients with negative sequencing results but highly suspected HLRCC. In addition, we analyzed the clinical characteristics and evaluated the genotype–phenotype correlations in Korean patients with HLRCC. Results: We identified six different pathogenic or likely pathogenic FH variants in six of the 13 patients (46.2%). The variants included two nonsense variants, two splicing variants, one frameshift variant, and one missense variant. Of the six variants, two (33.3%) were novel (c.132+1G>C, and c.243dup). RCC and early-onset uterine leiomyoma were frequently observed in families with HLRCC, while cutaneous leiomyoma was less common. No significant genotype–phenotype correlation was observed. Conclusions: We describe the genotypic and phenotypic spectrum in a small series of Korean patients with HLRCC. Our data reveal the unique characteristics of Korean patients with HLRCC and suggest a need for establishing an optimal diagnostic approach for them.
Abstract
Background: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant cancer predisposition syndrome. HLRCC is characterized by the development of cutaneous leiomyomas, early-onset uterine leiomyomas, and HLRCC-associated renal cell cancer (RCC) and caused by germline fumarate hydratase (FH) deficiency. We investigated the genotypic and phenotypic characteristics of Korean patients with HLRCC. Methods: We performed direct sequencing analysis of FH in 13 patients with suspected HLRCC and their family members. A chromosomal microarray test was performed in female patients with negative sequencing results but highly suspected HLRCC. In addition, we analyzed the clinical characteristics and evaluated the genotype–phenotype correlations in Korean patients with HLRCC. Results: We identified six different pathogenic or likely pathogenic FH variants in six of the 13 patients (46.2%). The variants included two nonsense variants, two splicing variants, one frameshift variant, and one missense variant. Of the six variants, two (33.3%) were novel (c.132+1G>C, and c.243dup). RCC and early-onset uterine leiomyoma were frequently observed in families with HLRCC, while cutaneous leiomyoma was less common. No significant genotype–phenotype correlation was observed. Conclusions: We describe the genotypic and phenotypic spectrum in a small series of Korean patients with HLRCC. Our data reveal the unique characteristics of Korean patients with HLRCC and suggest a need for establishing an optimal diagnostic approach for them.
참고문헌 (27)
- Launonen V, "Inherited susceptibility to uterine leiomyomas and renal cell cancer", Proc Natl Acad Sci U S A, 98, pp.3387~3392 (2001)
- Moch H, "The 2016WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours", Eur Urol, 70, pp.93~105 (2016)
- Tomlinson IP, "Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer", Nat Genet, 30, pp.406~410 (2002)
- Toro JR, "Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America", Am J Hum Genet, 73, pp.95~106 (2003)
- Wei MH, "Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer", J Med Genet, 43, pp.18~27 (2006)
- Gardie B, "Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma", J Med Genet, 48, pp.226~234 (2011)
- Alam NA, "Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency", Hum Mol Genet, 12, pp.1241~1252 (2003)
- Smit DL, "Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis", Clin Genet, 79, pp.49~59 (2011)
- Bhola PT, "A retrospective review of 48individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC)", Fam Cancer, 17, pp.615~620 (2018)
- 최연주, "Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients", Cancer Research and Treatment, 51(4), pp.1549~1556 (2019), 대한암학회
- Park I, "Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures", BMC Urol, 19, pp.51~ (2019)
- Patel VM, "Hereditary leiomyomatosis and renal cell cancer syndrome: an update and review", J Am Acad Dermatol, 77, pp.149~158 (2017)
- Muller M, "Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers", Clin Genet, 92, pp.606~615 (2017)
- Richards S, "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Kuwada M, "Novel missense mutation in the FH gene in familial renal cell cancer patients lacking cutaneous leiomyomas", BMC Res Notes, 7, pp.203~ (2014)
- Noguchi G, "Hereditary leiomyomatosis and renal cell cancer without cutaneous manifestations in two Japanese siblings", Int J Urol, 25, pp.832~835 (2018)
- Zhao Z, "Novel FH mutation associated with multiple uterine leiomyomas in Chinese siblings", Mol Genet Genomic Med, pp.e1068~ (2019)
- Joseph NM, "Morphology and immunohistochemistry for 2SC and FH aid in detection of fumarate hydratase gene aberrations in uterine leiomyomas from young patients", Am J Surg Pathol, 39, pp.1529~1539 (2015)
- Siegler L, "Fumarate hydratase (FH) deficiency in uterine leiomyomas: recognition by histological features versus blind immunoscreening", Virchows Arch, 472, pp.789~796 (2018)
- Rabban JT, "Prospective detection of germline mutation of fumarate hydratase in women with uterine smooth muscle tumors using pathology-based screening to trigger genetic counseling for hereditary leiomyomatosis renal cell carcinoma syndrome: a 5-year single institutional experience", Am J Surg Pathol, 43, pp.639~655 (2019)
- Merino MJ, "The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome", Am J Surg Pathol, 31, pp.1578~1585 (2007)
- Chen YB, "Hereditary leiomyomatosis and renal cell carcinoma syndromeassociated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry", Am J Surg Pathol, 38, pp.627~637 (2014)
- Carlo MI, "Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma", JAMA Oncol, 4, pp.1228~1235 (2018)
- Koski TA, "Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer", Genes Chromosomes Cancer, 48, pp.544~551 (2009)
- Vocke CD, "Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma", Genes Chromosomes Cancer, 56, pp.484~492 (2017)
- Linehan WM, "Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer", JAMA, 273, pp.564~570 (1995)
- Zbar B, "Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development", J Urol, 177, pp.461~465 (2007)